Crypto investors look ahead to policy wins, propelling bitcoin to record high
Those hopes helped propel bitcoin to another high on Friday and gave a boost to U.S.-listed crypto stocks.
Starting on Monday, the House of Representatives will debate a series of crypto bills to provide the digital asset industry with the U.S. regulatory framework it has long demanded. Those demands have resonated with U.S. President Donald Trump, who has called himself the "crypto president" and urged policymakers to revamp rules in favor of the industry.
Trump himself is involved in several crypto ventures, including World Liberty Financial, a platform that his sons Eric and Don Jr. run.
Members of Congress are set to vote on the Genius Act, the Clarity Act, and the Anti-CBDC Surveillance State Act during "crypto week," as the industry's strained ties with Washington continue to thaw. The most significant bill is the Genius Act, which would create federal rules for stablecoins.
"Even if final passage stalls, the optics of legislative engagement are bullish," said Jag Kooner, head of derivatives at crypto exchange Bitfinex.
Bitcoin's surge has triggered a broader rally in the crypto market, with strong and sustained inflows into the related spot exchange-traded funds driving prices higher, said Nicolai Sondergaard, research analyst at Nansen.
The world's largest cryptocurrency was last up 3.3 per cent at $117,333.32, taking its gains for the year to 26 per cent. The digital asset has surged nearly 41 per cent in the last three months.
Bitcoin buyer and holder Strategy rose 1.9 per cent, while crypto miners Riot Platforms, Hut 8, and Mara Holdings gained between 0.7 per cent and 1.6 per cent.
"Investors are racing to take positions ahead of the extra publicity this event could attract," said Dan Coatsworth, investment analyst at AJ Bell, referring to "crypto week."
Rising confidence in bitcoin is resulting in investors chasing higher returns in smaller tokens. Ether, the second-largest token, was last up 5.13 per cent, while XRP and solana gained 9.7 per cent and 0.8 per cent, respectively.
The sector's total market value has swelled to about $3.67 trillion, according to data from CoinMarketCap.
'CRYPTO WEEK'
The House of Representatives is set to pass a series of crypto-related bills next week, including a bill that would establish a regulatory framework for stablecoins after Trump subsequently approves it.
Stablecoins, a type of cryptocurrency designed to maintain a constant value, usually a 1:1 dollar peg, are commonly used by crypto traders to move funds between tokens. Their use has grown rapidly in recent years, and proponents say they could be used to send payments instantly.
The bill, dubbed the Genius Act, received bipartisan support in the Senate, with several Democrats joining most Republicans to back the proposed federal rules. It is expected to pass the House and would then head to Trump, who has said he will sign the bill into law.
The bill would require tokens to be backed by liquid assets - such as U.S. dollars and short-term Treasury bills - and for issuers to publicly disclose the composition of their reserves on a monthly basis.
Crypto proponents say those rules could legitimize stablecoins, making banks, retailers, and consumers more comfortable with using them to transfer funds.
The House next week is also expected to pass a bill that aims to develop a regulatory regime for cryptocurrencies and would expand the Commodity Futures Trading Commission's oversight of the digital asset industry.
That bill, called the Clarity Act, has yet to be considered in the Senate, where it would need to pass before heading to Trump for final approval.
If signed into law, the bill would define when a cryptocurrency is a security or a commodity and clarify the Securities and Exchange Commission's jurisdiction over the sector, something crypto companies disputed during the Biden administration.
Crypto companies have argued that most crypto tokens should be classified as commodities instead of securities, which would enable platforms to more easily offer those tokens to their customers.
SKEPTICS RAISE RED FLAGS
Bitcoin's sharp rally has drawn caution from some corners of the market.
As crypto gets embedded in the traditional financial system, some analysts warned the hype may be outpacing reality.
"The (regulatory) backdrop has supported prices, and attention has turned to bitcoin's role in portfolios, with some likening the crypto-asset to 'digital gold.' This moniker is likely premature," said Dirk Willer, Citi's global head of macro, asset allocation, and emerging market strategy.
With likely volatility ahead, some analysts have cautioned investors to pause and weigh their time horizons before jumping in.
"It's hard not to be optimistic about bitcoin at this moment in time, but the risk of a fall in price or short-term pullback still exists," said Simon Peters, crypto analyst at online brokerage eToro.
Critics have argued the Trump administration is conceding too much to the crypto industry at the expense of protecting consumers and retail investors.
"I'm concerned that what my Republican colleagues are aiming for is another industry handout that gives the crypto lobby exactly its wish list," Democratic Senator Elizabeth Warren said this week.
Trump has faced criticism from political rivals and ethics experts over the potential for conflicts of interest regarding his family's crypto ventures.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNA
an hour ago
- CNA
Singapore's economy grew 4.3% in the second quarter of 2025: MTI advance estimates
SINGAPORE: Singapore's economy grew 4.3 per cent in the second quarter of 2025, faster than the 4.1 per cent growth in the first quarter of the year, according to advance estimates from the Ministry of Trade and Industry (MTI) on Monday (Jul 14). But the ministry flagged "significant uncertainty and downside risks" in the global economy in the second half of the year, given the "lack of clarity" over the United States' tariff policies. In April, MTI lowered Singapore's GDP growth forecast for 2025 to 0 per cent to 2 per cent, pointing to the effect of US President Donald Trump's tariffs. The ministry previously had a forecast of 1 per cent to 3 per cent growth for the year. Last week, the Trump administration started sending out letters on tariffs to several countries. The higher tariffs will kick in from Aug 1, and affects Singapore's neighbours such as Malaysia and Indonesia. Singapore's economic task force, which was set up to help businesses and workers navigate the impact of the US tariffs, announced that it would launch grants for companies by October this year. Advance gross domestic product estimates are mainly computed from data gathered in the first two months of the quarter. They are intended as an early indicator for the three-month period, and may be revised when more data is available. On a quarter-on-quarter seasonally-adjusted basis, Singapore's gross domestic product (GDP) expanded by 1.4 per cent in the second quarter, compared with a 0.5 per cent contraction in the first three months of the year.
Straits Times
an hour ago
- Straits Times
EU plans to engage more with other nations hit by US tariffs: Sources
The move comes as talks between the EU and the US have dragged on and continue to be stuck on several issues. The EU is preparing to step up its engagement with other countries hit by Mr Donald Trump's tariffs following a slew of new threats to the bloc and other US trading partners, according to people familiar with the matter. The contacts with nations including Canada and Japan could include the potential for coordination, said the people, who spoke on condition of anonymity to discuss private deliberations. The move comes as talks between the EU and the US have dragged on and continue to be stuck on several issues, including cars and tariff rates on agriculture. Member states were briefed on the status of talks on July 13. Earlier in the day, European Commission chief Ursula von der Leyen said the bloc will extend the suspension of trade countermeasures against the US until Aug. 1 to allow for further talks. The measures had been adopted in response to tariffs imposed earlier by Mr Trump on steel and aluminium before being paused a first time, and were due to snap back into place at midnight on July 15. 'At the same time, we will continue to prepare further countermeasures so we are fully prepared,' Ms von der Leyen told reporters in Brussels on July 13, while reiterating the EU's preference for a 'negotiated solution.' The current list of countermeasures would hit about €21 billion (S$31.4 billion) of US goods, while the EU has another one ready of about €72 billion, as well as some export controls, that will be presented to member states as early as July 14, said the people. Top stories Swipe. Select. Stay informed. Business From wellness zone to neurodivergent room: How companies are creating inviting, inclusive offices Singapore Govt will continue to support families, including growing group of seniors: PM Wong at PCF Family Day Singapore Swift action needed to stop vaping's slide from health risk to drug epidemic Singapore Experts call for legal agility to tackle influx of drug-laced vapes in Singapore Singapore askST Jobs: Feeling the pinch? Here's what to do if your pay rise is not matching inflation rate Opinion Hong Kong's past is disappearing, one icon at a time Asia Heaven sent? India's opposition parties build temples to woo Hindu voters Sport Sinner dethrones Alcaraz to capture maiden Wimbledon crown Ms Von der Leyen also said that the EU's anti-coercion instrument, the bloc's most powerful trade tool, won't be used at this point. 'The ACI is created for extraordinary situations,' she said. 'We are not there yet.' In a social media post responding to Mr Trump's announcement, French President Emmanuel Macron called for the speeding-up of preparations for credible countermeasures, including the anti-coercion tool, if no agreement is reached by Aug. 1. German Chancellor Friedrich Merz on July 14 evening said 30 per cent tariffs would hit exporters in Europe's largest economy 'to the core' if a negotiated solution in the trade conflict can't be found. Mr Merz said he was coordinating closely with other leaders to ensure tariffs of such magnitude don't come into force. 'That requires two things: unity in the European Union and good lines of communication with the American president,' the conservative leader told ARD in an interview. Mr Trump has sent letters to a slew of trading partners, tweaking tariff levels proposed in April and inviting them to further talks. In a letter published July 12, the US president warned the EU it would face a 30 per cent rate from August if better terms can't be negotiated. The EU had sought to conclude a tentative deal with the US to stave off higher tariffs, but Mr Trump's letter punctured recent optimism in Brussels over the prospects for an 11th-hour agreement. Other countries like Mexico, which has also been negotiating with the US, were surprised to receive similar letters. The EU is seeking a tariff no higher than 10 per cent on agricultural exports. An offset mechanism that some carmakers had pushed as a way to grant tariff relief to companies in return for investments in the US isn't under consideration for now, amid worries from the EU that it could shift production across the Atlantic. The bloc's negotiators are focusing talks on car tariffs instead, according to people familiar with the matter, who spoke on condition of anonymity to discuss private deliberations. Negotiations between the US and EU are expected to continue this week, said the people. The US and the EU have been discussing an initial deal that would see most EU exports hit with a 10 per cent tariff, with limited exemptions for some industries such as aviation and medical devices, Bloomberg previously reported. The EU has also been arguing for lower rates on spirits and wines, as well as mitigating through quotas the 50 per cent tariffs that Mr Trump has imposed on steel and aluminium. The US has proposed a 17 per cent tariff on agricultural products. Any initial agreement would also cover non-tariff barriers, economic security cooperation and strategic purchases. In addition to a universal levy now due in August, Mr Trump has also introduced 25 per cent levies on cars and parts, as well as double that on metals. The president is working to introduce sectoral levies in other areas, including pharmaceuticals and semiconductors, and recently announced a 50 per cent duty on copper. Any deal at this stage wouldn't automatically shield the EU from those sectoral measures, but the bloc continues to seek preferential treatment in the potentially affected industries. BLOOMBERG
Business Times
an hour ago
- Business Times
China biotech's stunning advance is changing the world's drug pipeline
[HONG KONG] The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way from their copycat days to challenge Western dominance on innovation. The number of novel drugs in China, for cancer, weight-loss and more, entering into development ballooned to over 1,250 last year, far surpassing the European Union and nearly catching up to the US's count of about 1,440, an exclusive Bloomberg News analysis showed. And the drug candidates from the land once notorious for cheap knock-offs and quality issues are increasingly clearing high bars to win recognition from both drug regulators and Western pharmaceutical giants. The findings, gleaned from an analysis of a database maintained by pharma intelligence solutions provider Norstella, show a fundamental shift in medical innovation's centre of gravity. With US President Donald Trump already threatening tariffs on the pharmaceutical sector, China's biotech advances, the scale of which is slowly coming into view, risk becoming another realm of superpower rivalry such as artificial intelligence and electric vehicles. 'The scale itself is not something we have seen before,' said Helen Chen, managing partner at LEK Consulting in Shanghai, who has advised healthcare companies on their China strategy since 2003. 'The products are here, they are attractive and they are fast.' This shift has occurred at an unprecedented pace. When China began to overhaul its drug regulatory system in 2015, the country had just 160 compounds to contribute to the global pipeline of innovative drugs, or less than 6 per cent of the total, behind Japan and the UK. The reforms helped streamline reviews, enforced data quality standards and improved transparency. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up The government's 'Made in China 2025' plan to elevate manufacturing in 10 priority sectors also helped spur a flurry of investments in biotechnology. Altogether, they unleashed a boom led by foreign-educated and -trained scientists and entrepreneurs. 'Not only is it now almost at parity with the US but it has that growth trajectory,' said Daniel Chancellor, vice-president of thought leadership at Norstella. 'It wouldn't be sensationalist to suggest that China will overtake the US in the next few years purely in terms of numbers of drugs that it's bringing through into its pipeline.' Bloomberg News' data analysis focuses on innovative drugs, excluding generic combinations, reformulations and biosimilars. Numbers aside, the more stunning leap is in the quality of Chinese biotech innovation. While there's constant debate in the pharmaceutical industry on whether Chinese firms are capable of producing not just effective but needle-shifting new therapies, there's growing recognition on multiple fronts. The world's strictest regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency, increasingly view Chinese drugs as generally promising enough to justify devoting extra resources to speed up their review, handing them coveted industry designations such as priority review, breakthrough therapy designation or fast track status. The country is now slightly ahead of the EU in earning such expedited reviews as of 2024, the data shows, a remarkable edge over a region that previously produced drugs such as Wegovy. One of the early exemplars of Chinese innovation is a cell therapy that has shown promise to potentially cure a deadly blood cancer. First developed in China by Legend Biotech, it is now marketed by Johnson & Johnson, having won a few expedited review designations along the way, and considered superior to a competing US-originated therapy. Still, the absolute number of China-originated drugs winning these designations trail their US counterparts by a large margin. Risk-aversion remains a factor holding back Chinese pharmaceutical innovation: So far, top companies tend to focus on making better versions of existing therapies or new iterations of older ideas, and few are pioneering novel treatment approaches that have never been tried before, an endeavour that comes with a high risk of failure and is still led by the US, Europe and, to a lesser extent, Japan. Nevertheless, the biggest Chinese breakthroughs are increasingly being snapped up by pharmaceutical giants for record sums, a sign that the perennial competition for the next blockbuster drug is also shifting East. A novel cancer drug from Akeso, which came out more effective than Merck's Keytruda in a Chinese study last year, has been likened to China biotech's DeepSeek moment, spawning a new wave of global interest. The promise of topping Keytruda, the world's top-selling drug, also swelled the valuation of Summit Therapeutics, which in 2022 paid US$500 million upfront for the development and marketing rights in the US and other regions. Other multinational players such as Merck, AstraZeneca and Roche Holding have also scooped up Chinese assets. In May, Pfizer set a new record as it announced a US$1.2 billion upfront deal with 3SBio for a cancer drug similar to Akeso's. These deals are increasing in both value and frequency, according to biopharma deal database DealForma, signalling confidence that China-originated drugs are competitive internationally and can bring in substantial revenue. The volume of potential candidates coming out of China means multinational companies, who have a constant need to add new products to the mix, can 'cast their net wider than ever before', Norstella's Chancellor said. A key advantage that has fuelled the rise of Chinese biotech firms is their ability to conduct research cheaper and faster at every step of the way, from lab experiments and animal testing to human trials. Creating a new drug from scratch is notoriously time-consuming and expensive, and China's massive patient pool and centralised hospital network have become a significant accelerator. An analysis of the time taken for drugs to conduct various testing stages shows that doctors in China can recruit for trials much faster, for early trials for cancer and obesity drugs, they can complete patient enrolment in half the time compared to the US. The difference in costs means Chinese companies can afford to run multiple trials simultaneously to find a winner, or quickly launch new projects once a scientific idea is validated by other groups. Since 2021, China has become the top location for clinical research, initiating the largest number of new trials globally, according to GlobalData. 'They can leapfrog competitors in other countries,' said Andy Liu, head of China at Novotech Health Holdings, which helps companies run clinical trials. To be sure, clinical data in China is just a start. US regulators have made it clear that China-only trial results, no matter how positive, are not sufficient to support drug approvals. Chinese biotechs with the ambition to sell their drugs overseas must prove that their treatment benefits can be replicated in non-Chinese patients, through complex and slower-moving global studies. It may still be a few years before a critical mass of drugs sourced from China wins US and EU approvals, the gold standard for high-quality treatments, and become widely used in the Western world, but many in the industry believe that's inevitable. China's innovators comprise both cutting-edge biotech startups founded by foreign-educated entrepreneurs and old-guard Chinese pharmaceutical companies such as Jiangsu Hengrui Pharmaceuticals, which used to be one of the country's biggest generic drugmakers. The company poured billions of US dollars into shifting to innovative research and development after Beijing's campaign to lower generic drug prices made that sector less profitable. It's now the world's top-ranked pharmaceutical company for the number of new innovative drugs added to the research pipeline in the period of 2020 to 2024. Of the 50 companies that generated the highest number of innovative drug candidates between 2020 and 2024, 20 of them were Chinese, compared to five in the five years before. 'As we move forward, the fact that there's high-quality innovation in China in terms of biotech will no longer be a novelty,' said Ali Pashazadeh, founder and managing director of healthcare advisory firm Treehill Partners in London. 'It will just be an accepted part of the norm.' At a time when China and the US are engaged in renewed geopolitical spats, the growth of China's biotech ecosystem is causing alarm among some American politicians and business leaders. A congressional commission warned that the US risks losing its leadership position in yet another industry critical to national security. 'Biotech is one of the forefronts of the US-China tech rivalry,' said Jack Burnham, research analyst at the think tank Foundation for Defense of Democracies. In addition to economic implications and possible military applications of biotech, China's leverage on innovative therapies may be weaponised in a future conflict, he said, if Americans become dependent on those medicines. The perception of threat has spurred calls for the US government to stymie China's biotech growth, through restrictions such as export controls on scientific equipment and barriers to investment, and boost the domestic biotech sector, including by changing the regulatory environment to emulate countries where clinical trials are run more quickly. Robert F Kennedy, the US Secretary of Health and Human Services, recently pledged to 'Make American Biotech Accelerate'. Despite the risks of the newly combative relationship between the world's two biggest economies, Chinese drugmakers such as Akeso have set their sights on bringing their therapies to developed Western markets. 'The pharma industry is the best industry in the world,' Akeso chief executive officer Michelle Xia said. 'At the end of the day, what we do benefits patients in China, in the US and all around the world.' BLOOMBERG
